BRNS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 mai 2024 @ 22:00):

Stats
Dagens volum	375.00
Gjennomsnittsvolum	23 677.00
Markedsverdi	91.54M
EPS	$0 ( 2024-05-10 )
Neste inntjeningsdato	( $-0.500 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0310 (1.32%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-10	Dawes Karen A	Buy	19 516	Share Option (Right to Buy)
2024-05-10	Scheeren Joseph	Buy	19 516	Share Option (Right to Buy)
2024-05-10	Phillips Anne M.	Buy	19 516	Share Option (Right to Buy)
2024-05-10	Hammacher Alex	Buy	19 516	Share Option (Right to Buy)
2024-05-10	Morgon Pierre A.	Buy	19 516	Share Option (Right to Buy)

INSIDER POWER
100.00
Last 6 transactions
Buy: 117 096 \| Sell: 0

Barinthus Biotherapeutics Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Barinthus Biotherapeutics Økonomi

Annual	2023
Omsetning:	$805 108
Bruttogevinst:	$802 000 (99.61 %)
EPS:	$-1.920

FY	2023
Omsetning:	$805 108
Bruttogevinst:	$802 000 (99.61 %)
EPS:	$-1.920

FY	2022
Omsetning:	$44.70M
Bruttogevinst:	$44.70M (100.00 %)
EPS:	$0.140

Financial Reports:

No articles found.

Barinthus Biotherapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.